ResMed Inkomsten in het verleden
Verleden criteriumcontroles 6/6
ResMed is de winst gegroeid met een gemiddeld jaarlijks percentage van 16.8%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 13.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 11.8% per jaar. Het rendement op eigen vermogen van ResMed is 21.4%, en het heeft een nettomarge van 23.1%.
Belangrijke informatie
16.8%
Groei van de winst
16.3%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 11.8% |
| Rendement op eigen vermogen | 21.4% |
| Nettomarge | 23.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Opbrengsten en kosten
Hoe ResMed geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 4,807 | 1,113 | 933 | 311 |
| 30 Jun 24 | 4,685 | 1,021 | 917 | 308 |
| 31 Mar 24 | 4,584 | 958 | 916 | 305 |
| 31 Dec 23 | 4,504 | 890 | 914 | 304 |
| 30 Sep 23 | 4,375 | 907 | 903 | 300 |
| 30 Jun 23 | 4,223 | 898 | 874 | 288 |
| 31 Mar 23 | 4,016 | 863 | 826 | 274 |
| 31 Dec 22 | 3,763 | 809 | 780 | 264 |
| 30 Sep 22 | 3,624 | 786 | 755 | 257 |
| 30 Jun 22 | 3,578 | 779 | 738 | 254 |
| 31 Mar 22 | 3,539 | 779 | 726 | 249 |
| 31 Dec 21 | 3,444 | 522 | 704 | 238 |
| 30 Sep 21 | 3,349 | 500 | 688 | 231 |
| 30 Jun 21 | 3,197 | 475 | 670 | 225 |
| 31 Mar 21 | 3,091 | 457 | 654 | 218 |
| 31 Dec 20 | 3,092 | 699 | 666 | 213 |
| 30 Sep 20 | 3,028 | 680 | 668 | 208 |
| 30 Jun 20 | 2,957 | 622 | 677 | 202 |
| 31 Mar 20 | 2,892 | 513 | 683 | 201 |
| 31 Dec 19 | 2,784 | 455 | 675 | 197 |
| 30 Sep 19 | 2,699 | 419 | 665 | 190 |
| 30 Jun 19 | 2,607 | 405 | 645 | 181 |
| 31 Mar 19 | 2,525 | 446 | 630 | 169 |
| 31 Dec 18 | 2,455 | 450 | 614 | 159 |
| 30 Sep 18 | 2,405 | 335 | 604 | 157 |
| 30 Jun 18 | 2,340 | 316 | 600 | 155 |
| 31 Mar 18 | 2,273 | 307 | 591 | 152 |
| 31 Dec 17 | 2,196 | 285 | 581 | 150 |
| 30 Sep 17 | 2,125 | 352 | 569 | 147 |
| 30 Jun 17 | 2,067 | 342 | 554 | 144 |
| 31 Mar 17 | 2,029 | 324 | 532 | 142 |
| 31 Dec 16 | 1,968 | 327 | 518 | 135 |
| 30 Sep 16 | 1,893 | 346 | 496 | 126 |
| 30 Jun 16 | 1,839 | 352 | 488 | 119 |
| 31 Mar 16 | 1,773 | 357 | 481 | 113 |
| 31 Dec 15 | 1,742 | 357 | 475 | 112 |
| 30 Sep 15 | 1,710 | 353 | 479 | 112 |
| 30 Jun 15 | 1,679 | 353 | 479 | 115 |
| 31 Mar 15 | 1,641 | 353 | 478 | 118 |
| 31 Dec 14 | 1,616 | 352 | 473 | 121 |
| 30 Sep 14 | 1,578 | 348 | 466 | 121 |
| 30 Jun 14 | 1,555 | 345 | 450 | 118 |
| 31 Mar 14 | 1,554 | 331 | 443 | 118 |
| 31 Dec 13 | 1,540 | 325 | 441 | 119 |
Kwaliteitswinsten: RMD heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (23.1%) RMD } zijn hoger dan vorig jaar (20.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van RMD is de afgelopen 5 jaar met 16.8% per jaar gegroeid.
Versnelling van de groei: De winstgroei van RMD over het afgelopen jaar ( 22.8% ) overtreft het 5-jarig gemiddelde ( 16.8% per jaar).
Winst versus industrie: De winstgroei RMD over het afgelopen jaar ( 22.8% ) overtrof de Medical Equipment -sector 12.2%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 21.4% ) van RMD wordt als hoog beschouwd.